19:23:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning MNTC 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning MNTC 0.00 SEK
2023-05-11 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-03 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning MNTC 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-03 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning MNTC 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning MNTC 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
2024-03-21 08:30:00

At today’s Capital Markets Day in Stockholm, Mentice executive management team will provide an update on the company’s growth strategy and give an overview of the company’s business model, financials, and operations, as well as the current trends and technological advancements in image-guided interventional therapies (IGIT). Mentice will also present updated financial targets.

The updated strategic direction consists of a plan to approach clinical activities and includes several strategic initiatives, among these are:

  • Continued investments into R&D to develop the next-generation technology
  • Standardization of the product portfolio
  • Further development of OEM (original equipment manufacturer) channels
  • Strategic collaboration with Mentice's largest industry clients.

To support the strategic direction, Mentice has updated its financial targets while clarifying that the company’s main ambition is continued growth while gradually improving profitability:

  • 20-30 per cent annual growth in Net sales.
  • EBITDA margin in the mid-term (three years) of 20 per cent with a longer-term target of 30 per cent EBITDA margin.
“This is formally our first capital market day since our IPO and we are looking forward to present strategi, product as well as two customer examples”, says Göran Malmberg, Mentice CEO, “we believe this is great opportunity to better explain what Mentice stand for.”

 In addition to the management team, Dr Demetrius Lopes, Director of Cerebrovascular and Comprehensive Stroke Center at Advocate Health Care, Chicago, USA, and Michael Lee, Director of EBR Systems, Ireland, will participate in the Capital Markets Day and discuss trends within IGIT and Mentice’s solutions.

The event will take place from 13:00 to 16:00 CET and will be held in person at Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm. The Capital Markets Day will also be webcast live for those unable to attend in person.

During the event, there will be a demonstration of Mentices products and solutions and an opportunity to ask questions directly to any of the presenters. For a complete agenda and more information about the event and to register, please visit: https://www.mentice.com/event/cmd-2024